Therapeutic Area

Urology

Therapeutic area intelligence for Urology with 7 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 7
Catalysts: 0
Companies: 2

Companies

Doncaster Pharma Limited →

Quadrant Pharmaceuticals →

Assets

Bladder Control →

Defect →

Vesomni →

Recent signals(7)

ClinicalJuly 1, 2026

Trial Comparing Suction Mini-PCNL to Standard PCNL for Kidney Stones Launched

A multicenter, international randomized controlled trial is underway to compare suction mini-PCNL with standard PCNL for 2-4 cm kidney stones.

ClinicalJune 29, 2026

Study on Tactile Feedback Training for Stress Urinary Incontinence in Pregnant Women

A clinical trial is evaluating the effectiveness of tactile feedback pelvic floor training compared to traditional methods for managing stress urinary incontinence in pregnant women.

RegulatoryJune 29, 2026

Defect Notification for Hiprex 1g Tablets Due to Braille Embossing Error

A Class 4 Medicines Defect Notification has been issued for Hiprex 1g tablets due to an error in Braille embossing on packaging.

ClinicalJune 29, 2026

New Device for Bladder Control in Men with SCI Shows Promise

A new device for noninvasive electrical stimulation aims to improve bladder control in men with spinal cord injury.

ClinicalJune 29, 2026

Study on Dietary Oxalate's Impact on Kidney Stone Disease and Immunity

A study is underway to assess the effects of dietary oxalate on urinary crystals and immune response in healthy individuals.

RegulatoryJune 28, 2026

Quadrant Pharmaceuticals Issues Class 4 Medicines Defect Notification for Vesomni Tablets

Quadrant Pharmaceuticals has reported Class 4 Medicines Defect due to incorrect barcode/GTIN on Vesomni tablets.

ClinicalJune 22, 2026

Trial Compares Tamsulosin Dose Escalation vs. Silodosin Switch in BPH-Related Urinary Retention

A randomized controlled trial is assessing the efficacy of tamsulosin dose escalation versus switching to silodosin in men with acute urinary retention due to BPH.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Kidney Stone Disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.